Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination includes antibiotics (neomycin, polymyxin B sulfate, bacitracin zinc) and a corticosteroid (hydrocortisone acetate). It is used to treat steroid-responsive inflammatory ocular conditions where bacterial infection or risk of infection exists. Neomycin and polymyxin B sulfates are active against a wide range of bacteria, including **Staphylococcus aureus**, **Streptococcus pneumoniae**, **Escherichia coli**, **Haemophilus influenzae**, **Klebsiella/Enterobacter** species, **Neisseria** species, and **Pseudomonas aeruginosa**. Bacitracin zinc also contributes to its antimicrobial activity. Hydrocortisone acetate reduces inflammation by suppressing the immune response. - **mechanisms**: The antibiotics work by inhibiting bacterial protein synthesis or disrupting cell membranes, while hydrocortisone acetate reduces inflammation by modulating immune responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Neomycin + Polymyxin B sulfate + Bacitracin zinc + Hydrocortisone acetate.